In the final portion of our discussion with Kimberly Kue-Tsemo, PharmD, she explores the key developments that could be the most significant push toward reducing pharmacy deserts.
|Articles|November 20, 2006
More systems available to help you provide MTM
So you've decided to provide medication therapy management (MTM) services to your Medicare Part D patients. Which technological product should you use to document and bill for these services? "Technology plays a very significant role," commented Stefan Merlo, Pharm.D., manager of pharmacy practice and operations at the National Association of Chain Drug Stores. "If pharmacies are not able to properly document and bill for their services, the process is not going to work."
Advertisement
Advertisement
Related to this article
In the second part of our interview with a collection of pharmacists from various backgrounds, they delve into the current developments highlighting the future of the profession.
Phase 2 trial results for the investigational vaccine were presented at IDWeek 2026 in Washington, DC, as the phase 3 program is currently underway.
The finalized rule is another step in the right direction for pharmacies calling for reform due to underwater reimbursement and other PBM pressures.
Allison Schneider, MPH, provides a detailed update regarding pharmacies’ impact within Medicare price negotiations and the legislation further impacting businesses.
The US health department announced policies that will allow for the compounding of 6 key peptides in US pharmacies.
New survey data add to the evidence regarding the safe and effective route of administering both COVID-19 and flu vaccines simultaneously.
This episode breaks down how PBMs conduct inventory audits, the sourcing and timing issues that trigger recoupments, and how pharmacies can prepare and push back.
Advertisement
Advertisement
Trending on Drug Topics
1
American Pharmacists Month: PBM Reform, Provider Status Key in Stopping Pharmacy Deserts
2
Pfizer Reports Strong Phase 2 Data for 25-Valent Pediatric PCV
3
PBMs Must Now Disclose Fees to Employer Plans Under Final DOL Rule
4
HHS Lets Pharmacies Compound Peptides as FDA Writes Official Rule
5